These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 36105816)

  • 1. Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.
    Jiang Q; Xie M; Chen R; Yan F; Ye C; Li Q; Xu S; Wu W; Jia Y; Shen P; Ruan J
    Front Immunol; 2022; 13():973601. PubMed ID: 36105816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Cell Membrane-Coated Nanoparticles for Cancer Management.
    Harris JC; Scully MA; Day ES
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
    Musetti S; Huang L
    ACS Nano; 2018 Dec; 12(12):11740-11755. PubMed ID: 30508378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy.
    Liu S; Wu J; Feng Y; Guo X; Li T; Meng M; Chen J; Chen D; Tian H
    Bioact Mater; 2023 Apr; 22():211-224. PubMed ID: 36246666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
    Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
    Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.
    Li Y; Ayala-Orozco C; Rauta PR; Krishnan S
    Nanoscale; 2019 Oct; 11(37):17157-17178. PubMed ID: 31531445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy.
    Raza F; Zafar H; Zhang S; Kamal Z; Su J; Yuan WE; Mingfeng Q
    Adv Healthc Mater; 2021 Mar; 10(6):e2002081. PubMed ID: 33586322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.
    Dobosz P; Stępień M; Golke A; Dzieciątkowski T
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.
    Chen J; Cong X
    Biomed Pharmacother; 2023 Jan; 157():113998. PubMed ID: 36399829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy.
    Xiong X; Zhao J; Pan J; Liu C; Guo X; Zhou S
    Nano Lett; 2021 Oct; 21(19):8418-8425. PubMed ID: 34546061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.
    Yang M; Chen Y; Zhu L; You L; Tong H; Meng H; Sheng J; Jin J
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine for advanced cancer immunotherapy.
    Diep YN; Kim TJ; Cho H; Lee LP
    J Control Release; 2022 Nov; 351():1017-1037. PubMed ID: 36220487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
    Grimaudo MA
    Adv Exp Med Biol; 2021; 1295():303-315. PubMed ID: 33543465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.